Redeye updates its estimates and fair value range following Tessin’s Q3 report, which came in slight...
Redeye comments on the acquisition of HPI Health Profile Institute, a provider of software solutions...
The guaranteed right issue will secure growth capital supporting the US launch and to advance the Eu...
Försäljning av sol- och lagringsprojekt i Arizona, USA Eolus har annonserat att bolaget säljer ett p...
Efter att Starboard köpt en majoritetspost… I slutet av september köpte det brasilianska investmentb...
BuildData's Group CEO, Gustave Geisendorf, presents at Redeye Theme: Property Technology.
’22e-‘24e EBIT estimates down 1-13% Orderbook growth likely to contract in tougher times Net cash ...
Analyst Group har med AlphaHelix Molecular Diagnostics AB ingått avtal om kontinuerlig analysbevakni...
Aspo upgraded its FY ‘22 guidance, thanks to ESL’s continued strong performance, and gave an update ...
Redeye positively views yesterday evening’s news that Xspray, through a directed share issue, has se...
Elanders presented a strong Q3 report, with group organic growth of 12% y/y and 81% adjusted EBIT gr...
Redeye briefly comments on Mendus presenting first clinical data from its ALISON phase I trial with ...
Redeye states its view on today’s September ARR update from Hoylu that closing its third quarter.
Redeye endorses that CLS has received an order worth SEK5.
Subgruppsresultaten från Chordates kliniska studie PM007 presenterades i samband med Migraine Trust ...
Genomför sitt tredje större förvärv… Nordic LEVEL Group (LEVEL) har meddelat att de avser att förvär...
Aspo sold its Telko Segment’s Russian operations for EUR 9.
Redeye comments on Jondetech's upcoming rights issue, which will inject well-needed cash that is lik...
Redeye comments on Tessin’s Q3 results, which came in higher than expected in terms of sales and low...
We revise our estimates due to the financial impact of the unsuccessful Semcon acquisition and accor...
